EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity

Lukas M Braun, Sophie Giesler, Geoffroy Andrieux, Roxane Riemer, Nana Talvard-Balland, Sandra Duquesne, Tamina Rückert, Susanne Unger, Stefanie Kreutmair, Melissa Zwick, Marie Follo, Alina Hartmann und 48 weitere

Cancer Cell · 2025-02 · 43 (2) · 269-291.e19

DOI: 10.1016/j.ccell.2025.01.004 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Cell, 2025-02. Verfasst von Lukas M Braun und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Faculty o…. Hauptthemen laut MEDLINE: Adiponectin, Immune Checkpoint Inhibitors, Inflammation, Neoplasms. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Krebshilfe, José Carreras Leukämie-Stiftung, Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune-related adverse events (irAEs) in cancer patients receiving immune checkpoint inhibitors (ICIs) cause morbidity and necessitate cessation of treatment. Comparing irAE treatments, we find that anti-tumor immunity is preserved in mice after extracorporeal photopheresis (ECP) but reduced with glucocorticosteroids, TNFα blockade, and α4β7-integrin inhibition. Local adiponectin production elicits a tissue-specific effect by reducing pro-inflammatory T cell frequencies in the colon while sparing tumor-specific T cell development. A prospective phase-1b/2 trial (EudraCT-No.2021-002073-26) with 14 patients reveals low ECP-related toxicity. Overall response rate for all irAEs is 92% (95% confidence interval [CI]: 63.97%–99.81%); colitis-specific complete remission rate is 100% (95% CI: 63.06%–100%). Glucocorticosteroid dosages could be reduced for all patients after ECP therapy. The ECP-adiponectin axis reduces intestinal tissue-resident memory T cell activation and CD4 + IFN-γ + T cells in patients with ICI-induced colitis without evidence of loss of anti-tumor immunity. In conclusion, we identify adiponectin as an immunomodulatory molecule that controls ICI-induced irAEs without blocking anti-tumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdiponectinImmune Checkpoint InhibitorsInflammationNeoplasmsColitisAnimalsHumansMiceFemaleMaleMiddle AgedAgedProspective StudiesMice, Inbred C57BL

Stichwörter der Autor:innen

adiponectinanti-tumor immunityarginase-1cancer immunotherapycolitisextracorporeal photopheresisimmune checkpoint inhibitionimmune-related adverse eventsimmunomodulationimmunosuppression

Substanzen

AdiponectinImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Department of Surgery, University Hospital Regensburg, Regensburg, Germany.
  • Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.

Förderung

  • Deutsche Krebshilfe
  • José Carreras Leukämie-Stiftung
  • Bundesministerium für Bildung und Forschung
  • National Institutes of Health
  • Deutsche Forschungsgemeinschaft
  • European Commission
  • European Research Council
  • Leukemia and Lymphoma Society

Zitieren

APA

Braun, L. M., Giesler, S., Andrieux, G., Riemer, R., Talvard-Balland, N., Duquesne, S., Rückert, T., Unger, S., Kreutmair, S., Zwick, M., Follo, M., Hartmann, A., Osswald, N., Melchinger, W., Chapman, S., Hutchinson, J. A., Haferkamp, S., Torster, L., Kött, J., …, & Zeiser, R. (2025). Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell, 43(2), 269-291.e19. https://doi.org/10.1016/j.ccell.2025.01.004

Vancouver

Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell. 2025;43(2):269-291.e19. doi:10.1016/j.ccell.2025.01.004

BibTeX
@article{Braun2025,
  author = {Braun, Lukas M and Giesler, Sophie and Andrieux, Geoffroy and Riemer, Roxane and Talvard-Balland, Nana and Duquesne, Sandra and Rückert, Tamina and Unger, Susanne and Kreutmair, Stefanie and Zwick, Melissa and Follo, Marie and Hartmann, Alina and Osswald, Natascha and Melchinger, Wolfgang and Chapman, Stefanie and Hutchinson, James A and Haferkamp, Sebastian and Torster, Leopold and Kött, Julian and Gebhardt, Christoffer and Hellwig, Dirk and Karantzelis, Nikolaos and Wallrabenstein, Till and Lowinus, Theresa and Yücel, Mehtap and Brehm, Niklas and Rawluk, Justyna and Pfeifer, Dietmar and Bronsert, Peter and Rogg, Manuel and Mattern, Sven and Heikenwälder, Mathias and Fusco, Stefano and Malek, Nisar P and Singer, Stephan and Schmitt-Graeff, Annette and Ceteci, Fatih and Greten, Florian R and Blazar, Bruce R and Boerries, Melanie and Köhler, Natalie and Duyster, Justus and Ihorst, Gabriele and Lassmann, Silke and Keye, Philip and Minguet, Susana and Schadendorf, Dirk and Ugurel, Selma and Rafei-Shamsabadi, David and Thimme, Robert and Hasselblatt, Peter and Bengsch, Bertram and Schell, Christoph and Pearce, Erika L and Meiss, Frank and Becher, Burkhard and Funke-Lorenz, Carolin and Placke, Jan-Malte and Apostolova, Petya and Zeiser, Robert},
  title = {Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {2},
  pages = {269--291.e19},
  doi = {10.1016/j.ccell.2025.01.004}
}
Kostenlos starten →